News

June 14, 2019

ME-401 Experimental Compound Reduces Tumor Burden in Follicular Lymphoma, Phase 1 Trial Shows

News

MEI Pharma‘s experimental compound ME-401 reduced tumor burden in 80% of patients with relapsed or refractory follicular lymphoma in a Phase 1 trial, the company said. Responses were comparable among ... Read more

June 13, 2019June 20, 2019

FDA Gives OK to Polivy plus Rituxan-Bendamustine Combo to Treat Advanced DLBCL

News

The U.S. Food and Drug Administration (FDA) has approved — with conditions — Genentech‘s Polivy (polatuzumab vedotin-piiq), used in combination with Rituxan (rituximab) and bendamustine (a chemotherapy), to treat adults with relapsed or ... Read more

June 11, 2019

Tyvyt Effective, Safe in Previously Treated Patients with Hodgkin’s Lymphoma, Phase 2 Trial Shows

News

Treatment with Tyvyt (sintilimab injection) was found safe and eased the tumor burden or led to cancer disappearance in nearly 3 out of 10 patients with relapsed or refractory classical ... Read more

June 7, 2019

Triple Therapy Combo Effective in Treating DLBCL Subtype, Data Suggest

News

People with the non-germinal center subtype of diffuse large B-cell lymphoma (non-GCB DLBCL) respond well to initial treatment with Rituxan (rituximab), Imbruvica (ibrutinib), and Revlimid (lenalidomide) — so well that ... Read more

June 6, 2019

Adcetris Combo Continues to Show Better Results Than Chemotherapy Alone, Phase 3 Update Reveals

News

Seattle Genetics‘ Adcetris (brentuximab vedotin) in combination with standard chemotherapy continues to show better clinical activity than bleomycin plus standard chemotherapy, as a front-line treatment for patients with Hodgkin’s lymphoma, updated ... Read more

June 4, 2019

Cancer Vaccine Shows Potential against iNHL in Early Results

News

A new cancer vaccine still in clinical testing showed potential for driving disease remission in patients with advanced indolent non-Hodgkin’s lymphoma (iNHL) and may help restore efficacy of immunotherapies, including ... Read more

May 28, 2019July 1, 2019

Preclinical Study Uncovers Resistance Mechanisms to Lymphoma Therapy and Potential Way to Overcome Them

News

Lymphoma cells can become resistant to therapy as they acquire novel genetic mutations, but a new study has found that they can also become resistant as they reprogram which genes ... Read more

May 23, 2019

IBI301 (Biosimilar of Rituxan) Meets Primary Endpoints in 2 Clinical Trials in China for B-cell Lymphomas

News

IBI301, a biosimilar of Rituxan (rituximab), behaves similarly in the body and has a similar efficacy as the original product in patients with B-cell cancers, according to results from two ... Read more

May 21, 2019

FDA Won’t Ban Sales of Breast Implants Linked to Lymphoma, But Considers Black Box Warning

News

In announcing that breast implants linked to anaplastic large-cell lymphoma (ALCL) can continue to be sold in the United States, the U.S. Food and Drug Administration (FDA) proposed assurances that the ... Read more

May 17, 2019

FDA Approves Venclexta-Gazyva Combo for Untreated CLL/SLL Patients

News

The U.S. Food and Drug Administration (FDA) has approved the double combination therapy of Venclexta (venetoclax) and Gazyva (obinutuzumab) for the treatment of adults with newly diagnosed chronic lymphocytic leukemia ... Read more